Form 4: Verona Pharma Director Sells Shares in $107/ADS Merger

Verona Pharma director Kenneth Cunningham reports the disposition of shares, RSUs, and options as part of the company's acquisition by Merck Sharp & Dohme LLC for $107 per ADS.

Summary

• Kenneth Cunningham, a Director of Verona Pharma plc, reported changes in his beneficial ownership of the company's securities.
• The transactions occurred on October 7, 2025, as a result of a scheme of arrangement under Part 26 of the UK Companies Act 2006.
• Verona Pharma plc is being acquired by Merck Sharp & Dohme LLC ('Parent') and Vol Holdings LLC ('Bidco') pursuant to a transaction agreement dated July 8, 2025.
• At the effective time of the scheme, each Ordinary Share (Scheme Share) converted into the right to receive $13.375 in cash.
• Each American Depositary Share (ADS) represents eight (8) Ordinary Shares, entitling ADS holders to receive $107 in cash per ADS.
• Cunningham disposed of 79,776 Ordinary Shares and 72,000 Ordinary Shares, resulting in zero beneficial ownership of Ordinary Shares following these transactions.
• Outstanding time-based restricted share unit (RSU) awards, including 72,000 RSUs held by Cunningham, became fully vested and converted into cash based on the ADS Consideration.
• Outstanding share options, including 200,000, 96,000, 240,000, and 64,000 options held by Cunningham, became fully vested and converted into cash if their exercise price was less than the ADS Consideration.

Sentiment

Score: 8

Explanation: The filing reports the successful execution of an acquisition, providing a clear cash exit for shareholders and vesting of equity awards for management. This is generally a positive outcome for investors, reflecting a premium for the company's assets.

Positives

• Shareholders of Verona Pharma plc are set to receive a fixed cash consideration of $13.375 per Ordinary Share or $107 per ADS, providing a clear exit strategy and liquidity.
• All outstanding time-based restricted share unit awards and eligible share options held by management, including Director Kenneth Cunningham, became fully vested and converted into cash, ensuring compensation for equity holders.

Negatives

• The acquisition means Verona Pharma plc will cease to be an independent publicly traded entity, removing its stock from the market.

Future Outlook

Verona Pharma plc's independent future outlook is concluded as the company is being acquired by Merck Sharp & Dohme LLC. The filing details the financial terms of this acquisition for shareholders and equity award holders.

Industry Context

This acquisition represents a strategic move by a major pharmaceutical company, Merck Sharp & Dohme LLC, to integrate Verona Pharma plc, likely for its pipeline or therapeutic assets. Such transactions are common in the biotechnology and pharmaceutical sectors as larger entities seek to expand their portfolios or acquire promising technologies.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive a cash payment of $13.375 per Ordinary Share or $107 per ADS, providing a definitive return on their investment.
• Employees (Management): Equity awards (RSUs and Share Options) held by management, including Director Kenneth Cunningham, became fully vested and converted into cash, ensuring their compensation is realized as part of the acquisition.

Next Steps

• Shareholders will receive the cash consideration of $13.375 per Ordinary Share or $107 per ADS.
• The company will likely be delisted following the completion of the acquisition.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Transaction, Acquisition, Merger, Merck Sharp & Dohme, Scheme of Arrangement, Restricted Share Unit, Share Options, Cash Consideration